Zobrazeno 1 - 10
of 197
pro vyhledávání: '"György, Kéri"'
Autor:
Johannes Brägelmann, Marcel A. Dammert, Felix Dietlein, Johannes M. Heuckmann, Axel Choidas, Stefanie Böhm, André Richters, Debjit Basu, Verena Tischler, Carina Lorenz, Peter Habenberger, Zhizhou Fang, Sandra Ortiz-Cuaran, Frauke Leenders, Jan Eickhoff, Uwe Koch, Matthäus Getlik, Martin Termathe, Muhammad Sallouh, Zoltán Greff, Zoltán Varga, Hyatt Balke-Want, Christopher A. French, Martin Peifer, H. Christian Reinhardt, László Örfi, György Kéri, Sascha Ansén, Lukas C. Heukamp, Reinhard Büttner, Daniel Rauh, Bert M. Klebl, Roman K. Thomas, Martin L. Sos
Publikováno v:
Cell Reports, Vol 20, Iss 12, Pp 2833-2845 (2017)
Kinase inhibitors represent the backbone of targeted cancer therapy, yet only a limited number of oncogenic drivers are directly druggable. By interrogating the activity of 1,505 kinase inhibitors, we found that BRD4-NUT-rearranged NUT midline carcin
Externí odkaz:
https://doaj.org/article/65260813004b4d5e8d198b9f59d2baa6
Autor:
Henrik Daub, Josef Wissing, György Kéri, Matt Cotten, Bert Klebl, Stefan Müller, Martina Weber, Alexander Kurtenbach, Stephanie Blencke, Klaus Godl, Zoltán Greff, Dirk Brehmer
Supplementary Methods and Figure from Cellular Targets of Gefitinib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61c7a36d033024c906dd8d464db7ab66
https://doi.org/10.1158/0008-5472.22361673.v1
https://doi.org/10.1158/0008-5472.22361673.v1
Autor:
Henrik Daub, Josef Wissing, György Kéri, Matt Cotten, Bert Klebl, Stefan Müller, Martina Weber, Alexander Kurtenbach, Stephanie Blencke, Klaus Godl, Zoltán Greff, Dirk Brehmer
Supplementary Table 2 from Cellular Targets of Gefitinib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fef01c4943db660c7fa2c6553b62f51
https://doi.org/10.1158/0008-5472.22333051.v1
https://doi.org/10.1158/0008-5472.22333051.v1
Autor:
Axel Ullrich, György Kéri, Henrik Daub, István Szabadkai, László Őrfi, Yuri P. Knyazev, Kirti Sharma, Yuri V. Cheburkin, Peter G. Knyazev, Yi-Xiang Zhang
Supplementary Table 1 from AXL Is a Potential Target for Therapeutic Intervention in Breast Cancer Progression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69242eef7a4abffe5f9f345eac010ab4
https://doi.org/10.1158/0008-5472.22375325
https://doi.org/10.1158/0008-5472.22375325
Autor:
Axel Ullrich, György Kéri, Henrik Daub, István Szabadkai, László Őrfi, Yuri P. Knyazev, Kirti Sharma, Yuri V. Cheburkin, Peter G. Knyazev, Yi-Xiang Zhang
Supplementary Methods and Materials, Figures 1-5 from AXL Is a Potential Target for Therapeutic Intervention in Breast Cancer Progression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17c655efb2408792af49402a78a819fa
https://doi.org/10.1158/0008-5472.22375328.v1
https://doi.org/10.1158/0008-5472.22375328.v1
Autor:
Henrik Daub, Josef Wissing, György Kéri, Matt Cotten, Bert Klebl, Stefan Müller, Martina Weber, Alexander Kurtenbach, Stephanie Blencke, Klaus Godl, Zoltán Greff, Dirk Brehmer
Supplementary Table 1 from Cellular Targets of Gefitinib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3881c8958e642fecbb5e0f473b8a051c
https://doi.org/10.1158/0008-5472.22361670
https://doi.org/10.1158/0008-5472.22361670
Autor:
Henrik Daub, Axel Ullrich, Matt Cotten, Stefan Müller, György Kéri, Zoltán Horváth, László Őrfi, Dirk Brehmer, Heidrun Degen, Martina Weber, Stephanie Blencke, Josef Wissing, Jan Eickhoff, Oliver J. Gruss, Klaus Godl
Supplementary Methods from Proteomic Characterization of the Angiogenesis Inhibitor SU6668 Reveals Multiple Impacts on Cellular Kinase Signaling
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::789ba711eb15997d730538decf8d62cc
https://doi.org/10.1158/0008-5472.22363805
https://doi.org/10.1158/0008-5472.22363805
Autor:
Henrik Daub, Josef Wissing, György Kéri, Matt Cotten, Bert Klebl, Stefan Müller, Martina Weber, Alexander Kurtenbach, Stephanie Blencke, Klaus Godl, Zoltán Greff, Dirk Brehmer
Targeted inhibition of protein kinases with small molecule drugs has evolved into a viable approach for anticancer therapy. However, the true selectivity of these therapeutic agents has remained unclear. Here, we used a proteomic method to profile th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46df888bca05c3069e009f3f92364397
https://doi.org/10.1158/0008-5472.c.6493059.v1
https://doi.org/10.1158/0008-5472.c.6493059.v1
Autor:
Henrik Daub, Axel Ullrich, Matt Cotten, Stefan Müller, György Kéri, Zoltán Horváth, László Őrfi, Dirk Brehmer, Heidrun Degen, Martina Weber, Stephanie Blencke, Josef Wissing, Jan Eickhoff, Oliver J. Gruss, Klaus Godl
Knowledge about molecular drug action is critical for the development of protein kinase inhibitors for cancer therapy. Here, we establish a chemical proteomic approach to profile the anticancer drug SU6668, which was originally designed as a selectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3077c98eee86ccde664df9808edb82aa
https://doi.org/10.1158/0008-5472.c.6493904.v1
https://doi.org/10.1158/0008-5472.c.6493904.v1
Autor:
Henrik Daub, Axel Ullrich, Matt Cotten, Stefan Müller, György Kéri, Zoltán Horváth, László Őrfi, Dirk Brehmer, Heidrun Degen, Martina Weber, Stephanie Blencke, Josef Wissing, Jan Eickhoff, Oliver J. Gruss, Klaus Godl
Supplementary Figure 1 from Proteomic Characterization of the Angiogenesis Inhibitor SU6668 Reveals Multiple Impacts on Cellular Kinase Signaling
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0756a04157a10dd2aec096fdfd2a8fbd
https://doi.org/10.1158/0008-5472.22363808.v1
https://doi.org/10.1158/0008-5472.22363808.v1